All News
CAR-T Cell Therapies in Refractory RMD
EULAR 2026 Press Release
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
Read Article
Progress of biologics/targeted therapy in SLE
We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being presented at EULAR 2026 Congress in London.
Read Article
#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow #EULARBest https://t.co/x1d4G1s0jw
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Izokibep IL-17A Affibody PsA
343 pts RCT PBO crossover wk16
52 wks data
ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52%
No diff between QW vs Q2W
AE Injection-site reactions, URTIs most common
No new safety signals
Looks like any other IL17Ai to me
#EULAR2026 #OP073 https://t.co/WiHT8Plitn
Aurelie Najm AurelieRheumo ( View Tweet)
At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met all endpoints. ESSPRI improved too! Could be because strict concom DMARD inc. GC protocol @RheumNow https://t.co/FEhXfNPvfG
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y
Links:
#EULAR2026 Abstr# OP06 9 TOGETHER-PsA: Adding tirzepatide to ixekizumab in #PsA + obesity achieved the primary composite (ACR50 + ≥10% weight loss) in 31.7% vs just 0.8% with IXE alone at 36 weeks (p<0.001). The first trial tackling PsA + obesity simultaneously @RheumNow https://t.co/0cDAj1y7OF
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
💊 Oral IL-23Ri for #PsA #PsO?
ICONIC RCT (n=216):
Yes! Icotrokinra improves pain & disease activity at week 16
#POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🛡️ Can secukinumab prevent #PsA?
SERENA real-world study (n=1,334):
Yes!
97% PsA-free at 5yrs
#POS0051 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
BKZ protect joints in #PsA long-term?
#POS0048: Phase 3 RCT+OLE (n=579):
74% no x-ray progression at 3 yrs,
across all subgroups 💪
#EULAR2026 @RheumNow https://t.co/BftcHDKS4l
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🤔 GUS or IL-17i for #PsA?
#POS0045: RW study:
Both! ~76% persistence & similar effectiveness
1141 pts @12mo #PsABIOnd 🌍
#EULAR2026 @RheumNow https://t.co/PyuaH5B5V1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045
Jiha Lee JihaRheum ( View Tweet)
What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease:
-No flare in INEB group; 6% flare in PBO-INEB
-10.9% serious infections
-1 pt discontinued due to low IgG
Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16.
-Improvement as early as Week 4
-Low viral infections. Common AE: nasopharyngitis & headache.
-Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 Still undecided which session to attend? Please find my Conference Preview in the field of #SLE #lupus #biologics #targetedtherapy @RheumNow 😃
https://t.co/0m2p8mEgCQ https://t.co/C3xa5rPp9q
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
